2020 Child Asthma Data: Prevalence Tables

Print
Related Pages
Table L3
Childa Lifetime Asthmab Prevalence
and Weighted Numberc by Age and State or Territory: BRFSS 2020
State Age Group Sample Sized Prevalence (Percent) Standard Error 95% CIe (Percent) Weighted Numberc 95% CIe Weighted Numberc
Totalf 0-4 9,638 6.0 0.70 (4.8–7.6) 799,779 (612,301–987,258)
Totalf 5-9 10,529 11.1 0.76 (9.7–12.6) 1,470,674 (1,264,498–1,676,850)
Totalf 10-14 16,570 13.6 0.67 (12.3–14.9) 1,812,088 (1,628,232–1,995,945)
Totalf 15-17 10,619 16.3 0.93 (14.6–18.2) 1,338,411 (1,178,055–1,498,766)
CA 0-4 199 8.6 2.85 (4.5–16.1) 207,611 (65,599–349,624)
CA 5-9 193 8.5 2.27 (4.9–14.1) 207,948 (95,171–320,726)
CA 10-14 333 11.3 2.06 (7.8–16.0) 298,373 (188,463–408,282)
CA 15-17 184 12.7 3.01 (7.8–19.8) 161,396 (82,573–240,218)
CT 0-4 319 16.5 4.13 (9.9–26.3) 29,995 (13,540–46,450)
CT 5-9 438 18.7 3.46 (12.8–26.4) 33,209 (19,582–46,835)
CT 10-14 660 18.7 2.76 (13.9–24.7) 36,699 (25,424–47,974)
CT 15-17 438 18.3 2.74 (13.5–24.3) 24,513 (17,197–31,829)
DC 0-4 122 4.6 2.44 (1.6–12.6) 2,047 (0–4,244)
DC 5-9 186 14.0 3.41 (8.5–22.1) 5,310 (2,557–8,064)
DC 10-14 123 22.4 4.40 (14.9–32.1) 6,686 (3,812–9,560)
DC 15-17 114 14.4 3.84 (8.4–23.6) 2,853 (1,273–4,434)
FL 0-4 326 6.0 2.46 (2.7–13.1) 66,990 (11,785–122,194)
FL 5-9 411 10.5 2.62 (6.4–16.9) 113,390 (56,839–169,942)
FL 10-14 659 12.8 2.47 (8.7–18.4) 141,492 (86,168–196,815)
FL 15-17 330 11.6 3.20 (6.6–19.4) 87,125 (37,140–137,110)
GA 0-4 304 11.3 3.34 (6.2–19.7) 74,736 (28,394–121,079)
GA 5-9 409 14.9 3.24 (9.6–22.5) 95,201 (51,343–139,060)
GA 10-14 585 18.0 2.32 (13.9–23.0) 116,657 (85,795–147,518)
GA 15-17 431 24.9 4.19 (17.6–33.9) 107,665 (64,289–151,040)
HI 0-4 404 6.6 1.65 (4.0–10.7) 5,497 (2,726–8,268)
HI 5-9 329 14.5 2.58 (10.1–20.3) 12,312 (7,705–16,919)
HI 10-14 590 17.7 2.14 (13.9–22.3) 13,257 (9,875–16,639)
HI 15-17 249 17.6 3.32 (12.0–25.1) 8,358 (5,013–11,703)
IN 0-4 313 4.9 1.40 (2.8–8.5) 20,413 (8,839–31,987)
IN 5-9 404 7.7 1.40 (5.4–10.9) 30,919 (19,701–42,136)
IN 10-14 649 8.3 1.18 (6.3–10.9) 33,100 (23,699–42,500)
IN 15-17 352 16.1 2.45 (11.9–21.5) 42,649 (28,887–56,411)
KS 0-4 501 4.2 1.26 (2.3–7.5) 7,880 (3,185–12,575)
KS 5-9 560 12.6 1.78 (9.5–16.5) 22,837 (16,174–29,500)
KS 10-14 815 10.9 1.26 (8.6–13.6) 19,999 (15,348–24,650)
KS 15-17 466 17.7 2.21 (13.8–22.5) 20,614 (15,213–26,015)
KY 0-4 175 (.–.) 5,487 (.–.)
KY 5-9 195 9.5 2.84 (5.2–16.7) 23,741 (9,292–38,190)
KY 10-14 281 16.0 3.04 (10.9–22.9) 46,712 (27,691–65,732)
KY 15-17 139 12.9 3.29 (7.7–20.8) 17,609 (8,416–26,801)
ME 0-4 313 5.7 2.32 (2.6–12.4) 3,383 (617–6,148)
ME 5-9 334 11.4 2.36 (7.5–16.9) 6,933 (3,972–9,894)
ME 10-14 531 19.6 2.60 (15.0–25.2) 12,298 (8,799–15,797)
ME 15-17 342 11.6 2.13 (8.0–16.4) 4,769 (3,020–6,518)
MA 0-4 137 7.4 2.80 (3.5–15.1) 22,966 (5,297–40,636)
MA 5-9 122 14.2 4.38 (7.6–25.1) 46,240 (16,142–76,339)
MA 10-14 161 13.4 4.12 (7.2–23.7) 36,217 (12,360–60,075)
MA 15-17 175 17.2 3.93 (10.8–26.3) 47,452 (24,755–70,148)
MI 0-4 334 4.4 1.32 (2.4–7.8) 23,508 (9,535–37,480)
MI 5-9 356 13.0 2.00 (9.6–17.4) 70,764 (48,823–92,704)
MI 10-14 405 16.6 2.33 (12.5–21.7) 94,638 (66,773–122,503)
MI 15-17 362 16.6 2.88 (11.7–23.0) 62,469 (38,803–86,136)
MN 0-4 653 1.7 0.48 (0.9–2.9) 5,845 (2,491–9,199)
MN 5-9 769 6.2 1.11 (4.3–8.8) 21,973 (14,022–29,925)
MN 10-14 1,413 10.1 1.05 (8.2–12.4) 33,837 (26,725–40,949)
MN 15-17 833 10.3 1.73 (7.3–14.2) 21,743 (14,276–29,210)
MS 0-4 332 8.2 1.77 (5.4–12.5) 14,041 (8,018–20,063)
MS 5-9 328 8.5 1.68 (5.7–12.4) 14,874 (8,956–20,792)
MS 10-14 410 19.2 2.55 (14.6–24.7) 36,273 (26,168–46,378)
MS 15-17 287 21.7 4.67 (13.9–32.2) 26,577 (12,926–40,227)
MO 0-4 472 5.8 1.49 (3.5–9.5) 19,674 (9,559–29,789)
MO 5-9 388 11.6 2.07 (8.1–16.3) 41,876 (26,418–57,335)
MO 10-14 610 13.1 1.80 (9.9–17.0) 46,087 (32,884–59,290)
MO 15-17 363 21.4 2.99 (16.1–27.8) 50,176 (34,500–65,851)
MT 0-4 266 2.7 1.07 (1.2–5.8) 1,705 (382–3,029)
MT 5-9 367 11.0 2.53 (6.9–17.0) 6,627 (3,416–9,839)
MT 10-14 479 9.5 1.49 (7.0–12.9) 5,718 (3,958–7,478)
MT 15-17 276 17.3 2.65 (12.7–23.1) 6,644 (4,598–8,690)
NE 0-4 724 3.1 1.09 (1.6–6.1) 4,054 (1,228–6,880)
NE 5-9 678 5.8 1.32 (3.7–9.0) 7,603 (4,132–11,074)
NE 10-14 1,154 9.3 1.24 (7.1–12.0) 11,844 (8,626–15,062)
NE 15-17 821 13.8 1.87 (10.5–17.9) 10,745 (7,719–13,772)
NV 0-4 75 (.–.) 0 (.–.)
NV 5-9 116 7.3 3.23 (3.0–16.7) 13,671 (1,713–25,630)
NV 10-14 154 10.4 3.29 (5.5–18.8) 19,927 (7,150–32,703)
NV 15-17 103 23.5 6.84 (12.8–39.3) 22,475 (7,186–37,765)
NH 0-4 141 5.3 2.70 (1.9–13.8) 3,334 (0–6,767)
NH 5-9 224 11.5 2.51 (7.4–17.4) 7,362 (4,187–10,537)
NH 10-14 345 17.2 2.61 (12.7–23.0) 11,701 (7,856–15,546)
NH 15-17 228 15.1 2.60 (10.6–20.9) 7,009 (4,545–9,472)
NJ 0-4 505 8.2 2.09 (5.0–13.4) 40,041 (19,063–61,018)
NJ 5-9 459 8.3 1.56 (5.7–12.0) 42,161 (26,252–58,069)
NJ 10-14 726 17.9 1.91 (14.5–22.0) 84,733 (65,398–104,068)
NJ 15-17 513 14.8 1.85 (11.5–18.8) 45,867 (34,137–57,598)
NM 0-4 273 2.9 1.22 (1.3–6.5) 3,635 (671–6,599)
NM 5-9 306 13.2 3.02 (8.3–20.3) 16,648 (8,742–24,553)
NM 10-14 616 13.3 2.28 (9.5–18.5) 16,045 (10,416–21,674)
NM 15-17 280 14.6 3.91 (8.5–24.0) 12,062 (5,263–18,861)
NY 0-4 205 5.8 2.16 (2.7–11.8) 61,156 (15,249–107,062)
NY 5-9 309 11.2 2.26 (7.5–16.5) 113,160 (67,997–158,322)
NY 10-14 287 15.8 2.82 (11.0–22.1) 170,032 (106,928–233,137)
NY 15-17 177 19.5 3.87 (13.0–28.2) 124,752 (73,548–175,957)
OH 0-4 631 4.7 1.25 (2.8–7.9) 30,121 (14,361–45,882)
OH 5-9 557 10.4 2.21 (6.8–15.6) 71,180 (40,041–102,319)
OH 10-14 933 11.7 1.46 (9.1–14.9) 77,949 (58,295–97,603)
OH 15-17 743 15.8 1.92 (12.4–20.0) 64,012 (47,699–80,326)
PA 0-4 221 5.3 2.05 (2.4–11.1) 34,020 (7,397–60,644)
PA 5-9 228 14.1 3.23 (8.9–21.7) 99,646 (51,256–148,037)
PA 10-14 315 20.7 3.79 (14.2–29.1) 144,853 (84,051–205,655)
PA 15-17 361 17.3 3.08 (12.0–24.1) 72,364 (44,586–100,142)
RI 0-4 199 7.1 2.92 (3.1–15.4) 3,676 (618–6,733)
RI 5-9 195 15.1 3.35 (9.6–22.9) 8,104 (4,345–11,864)
RI 10-14 387 20.5 2.86 (15.5–26.7) 10,806 (7,558–14,054)
RI 15-17 223 18.2 3.89 (11.7–27.0) 6,646 (3,586–9,706)
TX 0-4 489 4.4 1.72 (2.1–9.3) 90,671 (20,395–160,947)
TX 5-9 474 14.0 2.98 (9.1–20.9) 286,218 (158,890–413,546)
TX 10-14 1,040 11.6 2.08 (8.2–16.4) 213,968 (134,790–293,146)
TX 15-17 486 16.7 3.47 (10.9–24.6) 205,268 (113,505–297,031)
UT 0-4 606 3.1 0.95 (1.7–5.6) 7,928 (3,019–12,837)
UT 5-9 647 9.9 1.35 (7.5–12.8) 25,665 (18,535–32,795)
UT 10-14 1,200 9.8 1.14 (7.7–12.2) 24,617 (18,701–30,533)
UT 15-17 839 14.6 1.52 (11.9–17.9) 22,352 (17,509–27,194)
VT 0-4 212 (.–.) 393 (.–.)
VT 5-9 322 9.1 1.71 (6.2–13.0) 2,678 (1,679–3,677)
VT 10-14 415 14.9 2.49 (10.6–20.4) 4,467 (2,921–6,013)
VT 15-17 273 22.3 3.62 (16.0–30.2) 4,728 (3,015–6,441)
WI 0-4 187 2.7 1.88 (0.7–10.2) 8,972 (0–21,412)
WI 5-9 225 7.0 2.34 (3.6–13.2) 22,422 (7,407–37,438)
WI 10-14 294 12.5 2.98 (7.7–19.6) 43,105 (22,345–63,864)
WI 15-17 231 21.7 4.96 (13.5–32.9) 47,519 (22,226–72,813)
Territories
PR 0-4 238 6.3 1.74 (3.7–10.7) 10,899 (4,887–16,911)
PR 5-9 286 19.2 2.56 (14.6–24.7) 37,047 (26,473–47,620)
PR 10-14 409 16.2 2.02 (12.7–20.6) 29,094 (21,558–36,630)
PR 15-17 236 12.2 2.37 (8.3–17.7) 17,515 (10,490–24,539)

Notes: For additional information on methods and variable description, refer to “Technical Information, available at: https://www.cdc.gov/asthma/brfss/2020/child/brfsschildtechinfo.html
aAged 0-17
bLifetime question: Has a doctor, nurse or other health professional ever said that the child has asthma?
cWeighted number of respondents who answered the lifetime asthma question
dUnweighted number of respondents who answered the lifetime asthma question
eCI denotes confidence interval
fTotal includes data from 30 states and DC, but excludes Puerto Rico
‘.–./blank’: Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE)>30%

Asthma and Community Health Branch, National Center for Environmental Health
Centers for Disease Control and Prevention

View Page In: PDF - 50 KB